Longevity Vision Fund

Longevity Vision Fund is a venture capital firm established in 2019 and based in New York. With a focus on making longevity affordable and accessible, the firm manages a $100 million investment fund dedicated to accelerating breakthroughs in extending healthy human lifespans. It invests in companies engaged in preventive medicine, early detection, medical technologies, artificial intelligence in healthcare, longevity therapies, regenerative medicine, and healthcare infrastructure. The fund provides financing from Seed to Series C stages for biotech and life extension-focused companies that exhibit the potential for affordable longevity solutions and a clear vision for achieving significant milestones and market validation. As a Registered Investment Adviser, Longevity Vision Fund aims to drive innovation in the longevity sector.

Sourav Sinha

General Partner and Head of Strategy

20 past transactions

Senda Biosciences

Series C in 2022
Senda Biosciences, founded in 2017 by David Kolesky, Ignacio Martinez, and John Casey in Cambridge, Massachusetts, focuses on developing therapeutic applications for innovative treatments of human diseases. The company specializes in studying the molecular relationships between bacterial, botanical, and human cells to understand how these interactions influence health and disease. By gaining insights into these interspecies connections, Senda Biosciences aims to create novel categories of medicines and delivery methods, providing medical professionals with new tools to combat various illnesses.

Tessera Therapeutics

Series C in 2022
Tessera Therapeutics is an early-stage life sciences company focused on pioneering Gene Writing technology, which allows for the precise insertion of therapeutic messages into the human genome. This innovative approach aims to address diseases at their source by enabling both small and large genetic alterations. By building on recent advancements in gene therapy and gene editing, Tessera Therapeutics seeks to overcome existing limitations in these fields, enhancing their efficacy and reach. Founded by Flagship Pioneering, the company aspires to establish a new category in genetic medicine that can significantly improve patient outcomes and transform healthcare.

Biolinq

Series B in 2021
Biolinq Inc. is a San Diego-based company specializing in the development of innovative skin-applied electronic sensors designed to analyze body fluids and deliver health insights. Founded in 2012, Biolinq focuses on creating a digital health platform that facilitates biomonitoring solutions. Its flagship product is a minimally invasive electrochemical biosensor that continuously monitors various biomarkers in interstitial fluid, including glucose, ketones, and lactate. This technology enables diabetic patients to track their blood glucose levels without the discomfort associated with traditional monitoring methods. By providing actionable health information and insights, Biolinq aims to enhance metabolic health and improve the quality of life for individuals managing diabetes.

Laronde

Series B in 2021
Laronde is a biotechnology company that specializes in developing an eRNA-based therapeutic platform designed to express a variety of proteins within the body. Founded in 2017 by Flagship Labs, Laronde's innovative Endless RNA technology is engineered to be persistent and non-immunogenic, allowing for repeat dosing and offering flexibility in both formulation and delivery. This platform aims to enhance the predictability and efficacy of new medicines, facilitating the development of therapeutics that can address a wide range of diseases. As Laronde continues to scale its operations, it focuses on advancing multiple programs simultaneously, positioning itself as a key player in the future of medicine.

Exo

Series C in 2021
Exo is a medical device startup focused on revolutionizing ultrasound technology for imaging and therapeutic applications. The company has developed a handheld ultrasound platform that integrates advanced nano-materials, innovative sensor technologies, and sophisticated signal processing with the cost advantages of semiconductor manufacturing. This approach allows Exo to provide high-quality, affordable, and user-friendly medical imaging solutions. By enabling healthcare professionals to make critical, real-time decisions, Exo aims to enhance patient outcomes significantly. The company's commitment to accessibility and ease of use in medical imaging represents a significant advancement in the field, making effective diagnostic tools available at an unprecedented price point.

Senda Biosciences

Series B in 2021
Senda Biosciences, founded in 2017 by David Kolesky, Ignacio Martinez, and John Casey in Cambridge, Massachusetts, focuses on developing therapeutic applications for innovative treatments of human diseases. The company specializes in studying the molecular relationships between bacterial, botanical, and human cells to understand how these interactions influence health and disease. By gaining insights into these interspecies connections, Senda Biosciences aims to create novel categories of medicines and delivery methods, providing medical professionals with new tools to combat various illnesses.

Tessera Therapeutics

Series B in 2021
Tessera Therapeutics is an early-stage life sciences company focused on pioneering Gene Writing technology, which allows for the precise insertion of therapeutic messages into the human genome. This innovative approach aims to address diseases at their source by enabling both small and large genetic alterations. By building on recent advancements in gene therapy and gene editing, Tessera Therapeutics seeks to overcome existing limitations in these fields, enhancing their efficacy and reach. Founded by Flagship Pioneering, the company aspires to establish a new category in genetic medicine that can significantly improve patient outcomes and transform healthcare.

Valo Health

Series B in 2021
Valo Health is a technology company focused on transforming the drug discovery and development process through the integration of human and machine intelligence. By leveraging machine learning, cloud computing, and extensive data analysis, Valo Health's platform facilitates the identification of previously unknown connections between genetic markers and diseases. This human-centric approach supports clients in the healthcare sector in the development of treatments for various conditions, including oncology, neurodegenerative diseases, and cardiovascular issues. Through its innovative platform, Valo Health aims to accelerate the creation of impactful therapies.

LyGenesis

Convertible Note in 2020
LyGenesis, Inc. is a biotechnology company focused on organ regeneration, headquartered in Pittsburgh, Pennsylvania, and founded in 2017. The company has developed a pioneering technology that utilizes a patient's lymph nodes as bioreactors to facilitate the regrowth of ectopic organs. Its primary target for clinical development is liver regeneration, aimed at supporting individuals with end-stage liver disease. In addition to liver regeneration, LyGenesis is exploring therapeutic opportunities for other organs, including the thymus, pancreas, and kidney. The innovative approach enables surgeons to regrow functioning organs within a patient's own body, offering potential solutions for organ transplantation and regeneration.

Eko Health

Series C in 2020
Eko Health is a leading digital health company advancing how healthcare professionals detect and monitor heart and lung disease with its portfolio of digital stethoscopes, patient and provider software, and AI-powered analysis. Its FDA-cleared platform is used by hundreds of thousands of healthcare professionals worldwide, allowing them to detect earlier and with higher accuracy, diagnose with more confidence, manage treatment effectively, and ultimately give their patients the best care possible. Eko Health is headquartered in Emeryville, California, with over $125 million in funding from Highland Capital Partners, Questa Capital, Artis Ventures, DigiTx Partners, NTTVC, Morningside Technology Ventures Limited, Mayo Clinic, Sutter Health, and others. For more information visit www.ekohealth.com.

Deep Longevity

Series A in 2020
Deep Longevity, Inc. is a biotechnology company focused on developing innovative solutions for aging and longevity. Founded in 2016 and based in Hong Kong, the company specializes in creating aging and longevity clocks tailored for preventative medicine organizations, health clubs, insurance companies, and aging centers. Its offerings include Longevity Cloud, a platform that hosts deep aging clocks, and Young.AI, a web and mobile application designed to support longevity initiatives. Deep Longevity also develops multifactorial tools known as deep aging clocks to measure biological age, alongside a recommendation engine aimed at suggesting longevity interventions. The company employs advanced AI techniques to harness various data types, including clinical blood tests and other biological metrics, to enhance the accuracy of biological age predictions.

4D Molecular Therapeutics

Series C in 2020
4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company based in Emeryville, California, focused on developing innovative gene therapies for unmet medical needs. The company utilizes targeted and evolved adeno-associated virus (AAV) vectors to create its product candidates, which are concentrated in the therapeutic areas of ophthalmology, cardiology, and pulmonology. Key candidates in its portfolio include 4D-125, currently in a Phase I/II trial for X-linked retinitis pigmentosa, and 4D-110, undergoing Phase I trials for choroideremia. Additionally, 4D-310 is in Phase I/II trials for Fabry disease, while investigational drugs 4D-150 and 4D-710 are being developed for wet age-related macular degeneration and cystic fibrosis lung disease, respectively. Founded in 2013, 4D Molecular Therapeutics aims to advance its gene therapies to address significant health challenges.

Sigilon Therapeutics

Series B in 2020
Sigilon Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing functional cures for patients with chronic diseases. Founded in 2015, the company aims to create immune-protected, engineered human cells that restore normal physiological functions without the risk of fibrosis or immune rejection. Its lead product candidate, SIG-001, is currently in Phase I/II clinical trials for preventing bleeding episodes in patients with moderate to severe Hemophilia A. Additionally, Sigilon is advancing other candidates, including SIG-005, which targets non-neurological manifestations of mucopolysaccharidosis type 1, and SIG-002, designed to replace islet cells for treating type 1 diabetes. The company's innovative Shielded Living Therapeutics platform leverages advances in cell engineering and proprietary biocompatible materials to offer stable and durable therapeutic solutions for a variety of chronic conditions.

LyGenesis

Debt Financing in 2019
LyGenesis, Inc. is a biotechnology company focused on organ regeneration, headquartered in Pittsburgh, Pennsylvania, and founded in 2017. The company has developed a pioneering technology that utilizes a patient's lymph nodes as bioreactors to facilitate the regrowth of ectopic organs. Its primary target for clinical development is liver regeneration, aimed at supporting individuals with end-stage liver disease. In addition to liver regeneration, LyGenesis is exploring therapeutic opportunities for other organs, including the thymus, pancreas, and kidney. The innovative approach enables surgeons to regrow functioning organs within a patient's own body, offering potential solutions for organ transplantation and regeneration.

Insilico Medicine

Series B in 2019
Insilico Medicine, Inc. is a biotechnology company that leverages artificial intelligence (AI) to transform drug discovery, biomarker development, and aging research. Founded in 2014 and based in Baltimore, Maryland, the company has established itself as a pioneer in applying advanced AI techniques, such as generative adversarial networks and reinforcement learning, to create novel molecular structures for various diseases, including cancer and age-related conditions. Insilico Medicine operates an integrated platform that covers all stages of drug discovery, from initial research to clinical trial analysis. Its projects include Pharma.AI, which offers machine learning services to various sectors, and Young.AI, a platform focused on aging predictors. The company also pursues internal drug discovery initiatives targeting diseases like Alzheimer's and Parkinson's, and has partnered with Life Extension to produce nutraceutical products utilizing deep learning and bioinformatics. Additionally, Insilico Medicine provides consumer applications aimed at enhancing health and longevity.

Juvenescence

Series B in 2019
Juvenescence Limited is a British Virgin Islands-based holding company focused on investing in the fields of human aging and longevity. The company aims to develop a comprehensive ecosystem of assets that target aging, age-related diseases, and regenerative medicine. By leveraging advancements in scientific and medical research, Juvenescence seeks to create therapeutics that significantly extend both healthspan and lifespan. Their approach involves forming partnerships with leading scientists and research institutions, in-licensing compounds from academia and industry, and developing novel therapies based on a deep understanding of the biological mechanisms of aging. Juvenescence's initiatives also encompass therapeutic strategies aimed at promoting healthy aging, metabolic health, and brain health, with the ultimate goal of addressing the societal implications of an aging population.

Exo

Series B in 2019
Exo is a medical device startup focused on revolutionizing ultrasound technology for imaging and therapeutic applications. The company has developed a handheld ultrasound platform that integrates advanced nano-materials, innovative sensor technologies, and sophisticated signal processing with the cost advantages of semiconductor manufacturing. This approach allows Exo to provide high-quality, affordable, and user-friendly medical imaging solutions. By enabling healthcare professionals to make critical, real-time decisions, Exo aims to enhance patient outcomes significantly. The company's commitment to accessibility and ease of use in medical imaging represents a significant advancement in the field, making effective diagnostic tools available at an unprecedented price point.

Freenome

Series B in 2019
Freenome, Inc. is an artificial intelligence genomics biotech company based in South San Francisco, California, founded in 2014. The company focuses on developing accurate, accessible, and non-invasive blood tests for the early detection of cancer and treatment selection. Utilizing a proprietary multi-omics platform, Freenome employs advanced algorithms to analyze cell-free genomic data, which aids in identifying early-stage cancers and other diseases. This innovative approach aims to transform disease management by enabling timely interventions and proactive treatment strategies. In addition to its diagnostic solutions, Freenome also offers clinical research services to further advance cancer detection and management.

Valo Health

Series A in 2019
Valo Health is a technology company focused on transforming the drug discovery and development process through the integration of human and machine intelligence. By leveraging machine learning, cloud computing, and extensive data analysis, Valo Health's platform facilitates the identification of previously unknown connections between genetic markers and diseases. This human-centric approach supports clients in the healthcare sector in the development of treatments for various conditions, including oncology, neurodegenerative diseases, and cardiovascular issues. Through its innovative platform, Valo Health aims to accelerate the creation of impactful therapies.

Deciduous Therapeutics

Venture Round in 2019
Deciduous Therapeutics is a biotechnology company focused on developing innovative immune-modulatory therapies aimed at addressing age-related diseases. The company specializes in creating novel molecules that activate the body's natural immune surveillance mechanisms to selectively eliminate senescent cells, which are associated with various age-related conditions. Led by Anil Bhushan, a professor at UCSF, and Robin Mansukhani, an experienced biotech entrepreneur, Deciduous Therapeutics is dedicated to promoting a healthier lifespan through its pioneering approach to therapeutics in the aging sector.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.